Stemchymal® for Polyglutamine Spinocerebellar Ataxia

Summary

The purpose of the clinical trial is to study the therapeutic efficacy and safety of Stemchymal® infusions for polyglutamine spinocerebellar ataxia treatment by a randomized, double-blind, placebo-controlled study design. Eligible subjects will receive Stemchymal® through intravenous infusion.

Timeline

Start

2025-06-01

Primary completion

2028-06-01

Completion

2028-06-01

Drugs

Indications